Artificial antigen presenting cells (aAPC) are cell-based or synthetic material-based three-dimensional platforms capable of activating an anti-tumor T cell response.
Adoptive T cell therapy has shown great promise in mediating tumor regression, yet it is an extremely costly and time-consuming process to isolate patients’ cells, expand them to large enough numbers and reinject patients.
